How FDA Withdraws A Drug
This article was originally published in RPM Report
Executive Summary
FDA is weighing whether to pull GlaxoSmithKline's Avandia and Abbott Laboratories' Meridia off the market. Past examples demonstrate the final decision on whether to remove a drug or keep it on the market is a messy process made by a select number of government officials.
You may also be interested in...
The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
FDA’s top drug regulator sat down for us for an interview about the agency’s efforts to build a higher quality regulatory system in the US—one that focuses on the “content” of regulatory standards rather than just the process. The discussion touched on the need for new and improved standards in classes like weight loss and rheumatology (albeit for very different reasons); the characteristics that make for good drug reviewers (and their managers); and on the drug center’s responsibility for preserving private sector drug development.
Accelerated Withdrawal in Action: The Avastin Hearing Process
The June hearing on the status of Genentech’s metastatic breast cancer indication for Avastin will focus on a long list of substantive disagreements about the data. But any sponsor interested in the future of the accelerated approval process should study the back-and-forth in the hearing process itself.
Lessons Learned: How Avandia is Changing the Way FDA Does Business
FDA learned two important lessons from the Avandia debacle. First, the agency needs to be a better communicator—which means telling the public more about what it knows (and doesn’t know) about the safety of marketed products. But Avandia is also leading the agency to rethink what should be required to demonstrate safety, especially for chronic care therapies. Both could mean big changes for industry.